Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:SAGENASDAQ:SUPNNASDAQ:VYGRNASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSAGESage Therapeutics$9.20+1.3%$7.50$4.62▼$13.47$575.79M0.291.30 million shs3.01 million shsSUPNSupernus Pharmaceuticals$32.00-0.2%$32.26$25.66▼$40.28$1.79B0.7477,192 shs212,566 shsVYGRVoyager Therapeutics$3.28+2.5%$3.22$2.65▼$9.55$181.52M0.85481,437 shs303,242 shsXENEXenon Pharmaceuticals$34.70+4.0%$32.54$26.74▼$46.00$2.66B1.1630,958 shs492,450 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSAGESage Therapeutics+1.27%-0.92%+40.81%+34.04%-13.42%SUPNSupernus Pharmaceuticals-0.23%+2.55%-0.73%-2.28%+23.01%VYGRVoyager Therapeutics+2.50%+10.44%0.00%+6.15%-57.57%XENEXenon Pharmaceuticals+4.00%+7.78%+12.97%+18.04%-3.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSAGESage Therapeutics3.2244 of 5 stars2.02.00.04.02.31.70.6SUPNSupernus Pharmaceuticals2.5737 of 5 stars2.22.00.04.12.10.00.0VYGRVoyager Therapeutics3.6874 of 5 stars3.61.00.04.61.10.80.6XENEXenon Pharmaceuticals3.3237 of 5 stars4.52.00.00.02.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSAGESage Therapeutics 2.00Hold$8.93-2.85% DownsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0012.52% UpsideVYGRVoyager Therapeutics 3.13Buy$13.39308.23% UpsideXENEXenon Pharmaceuticals 3.00Buy$54.8257.96% UpsideCurrent Analyst Ratings BreakdownLatest XENE, SUPN, SAGE, and VYGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025SAGESage TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.006/17/2025SAGESage TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.506/17/2025SAGESage TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ Hold$8.00 ➝ $9.006/17/2025SAGESage TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$12.006/17/2025SAGESage TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$8.00 ➝ $8.506/16/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025XENEXenon PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.005/13/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.005/13/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$53.00 ➝ $53.005/13/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSAGESage Therapeutics$41.24M13.96N/AN/A$7.60 per share1.21SUPNSupernus Pharmaceuticals$661.82M2.71$4.16 per share7.69$18.76 per share1.71VYGRVoyager Therapeutics$80M2.27N/AN/A$5.49 per share0.60XENEXenon Pharmaceuticals$9.43M282.38N/AN/A$9.90 per share3.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%7/30/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1128.8222.22N/A9.27%12.23%9.17%8/5/2025 (Estimated)VYGRVoyager Therapeutics-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.23N/AN/AN/AN/A-32.44%-30.84%8/14/2025 (Estimated)Latest XENE, SUPN, SAGE, and VYGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025SAGESage Therapeutics-$0.96N/AN/AN/A$16.69 millionN/A5/12/2025Q1 2025XENEXenon Pharmaceuticals-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSAGESage TherapeuticsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSAGESage TherapeuticsN/A9.139.13SUPNSupernus PharmaceuticalsN/A2.442.26VYGRVoyager TherapeuticsN/A6.106.10XENEXenon PharmaceuticalsN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSAGESage Therapeutics99.22%SUPNSupernus PharmaceuticalsN/AVYGRVoyager Therapeutics48.03%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipSAGESage Therapeutics5.50%SUPNSupernus Pharmaceuticals8.80%VYGRVoyager Therapeutics6.39%XENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million51.06 millionOptionableVYGRVoyager Therapeutics10055.34 million51.80 millionOptionableXENEXenon Pharmaceuticals21076.73 million72.50 millionOptionableXENE, SUPN, SAGE, and VYGR HeadlinesRecent News About These CompaniesXenon Appoints CEO Ian Mortimer as Interim CFOJuly 3 at 6:32 PM | tipranks.comXenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - NasdaqJune 29, 2025 | nasdaq.comXenon Pharmaceuticals Joins Russell 3000® and 2000® IndexesJune 27, 2025 | tipranks.comXenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual ReconstitutionJune 27, 2025 | quiverquant.comQXenon Joins the Russell 3000® and Russell 2000® IndexesJune 27, 2025 | financialpost.comFXenon Joins the Russell 3000® and Russell 2000® IndexesJune 27, 2025 | globenewswire.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2025 | globenewswire.comXenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)June 26, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Below 50 Day Moving Average - What's Next?June 25, 2025 | marketbeat.comXenon Announces Appointment of Darren Cline as Chief Commercial OfficerJune 24, 2025 | globenewswire.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Down 3.4% - Here's WhyJune 16, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from AnalystsJune 15, 2025 | marketbeat.comTraders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)June 12, 2025 | marketbeat.comXenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?June 11, 2025 | zacks.comCantor Fitzgerald Estimates XENE FY2026 EarningsJune 10, 2025 | marketbeat.comXenon to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2025 | globenewswire.comFair Value analysis proves accurate as XENE drops 37% from February 2024 peakMay 21, 2025 | investing.comWhy Xenon Pharmaceuticals Inc. (XENE) Declined on TuesdayMay 15, 2025 | insidermonkey.comPolarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society eventsMay 15, 2025 | proactiveinvestors.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXENE, SUPN, SAGE, and VYGR Company DescriptionsSage Therapeutics NASDAQ:SAGE$9.20 +0.12 (+1.27%) Closing price 07/3/2025 02:52 PM EasternExtended Trading$9.20 0.00 (0.00%) As of 07/3/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Supernus Pharmaceuticals NASDAQ:SUPN$32.00 -0.08 (-0.23%) Closing price 07/3/2025 01:31 PM EasternExtended Trading$32.00 0.00 (0.00%) As of 07/3/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.Voyager Therapeutics NASDAQ:VYGR$3.28 +0.08 (+2.50%) Closing price 07/3/2025 03:33 PM EasternExtended Trading$3.20 -0.07 (-2.29%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Xenon Pharmaceuticals NASDAQ:XENE$34.70 +1.33 (+4.00%) As of 07/3/2025 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.